Ensysce Biosciences Stock Pattern Recognition Inverted Hammer
| ENSC Stock | USD 0.41 -0.02 -4.65% |
| Symbol |
Recognition |
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was eleven with a total number of output elements of fifty. The function did not return any valid pattern recognition events for the selected time horizon. The Inverted Hammer pattern indicates that the buyers drove prices of Ensysce Biosciences up, at some point during the period, but encountered selling pressure which drove prices back down to close near to where they opened.
Ensysce Biosciences Technical Analysis Modules
Most technical analysis of Ensysce Biosciences help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Ensysce from various momentum indicators to cycle indicators. When you analyze Ensysce charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614 PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse and PF26810, an extended-release prodrug of methadone for opioid use disorder. Ensysce Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. Liquidity and trading activity can influence how quickly new information is reflected in Ensysce Biosciences's price. Lower trading activity may introduce occasional variability in execution conditions. Ensysce Biosciences has a market cap of 1.48 M, ROE of -2.94%.
Methodology
Unless otherwise specified, financial data for Ensysce Biosciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Ensysce (USA Stocks:ENSC) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Ensysce Biosciences may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardBecome your own money manager
Tracking Ensysce Biosciences inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Bond Analysis Now
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. |
| All Next | Launch Module |
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Software Invested few shares | |
 | FinTech Invested over 20 shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Adviser Favorites Invested few shares | |
 | Momentum Invested few shares | |
 | Advertising Invested few shares | |
 | Corona Opportunity Invested few shares | |
 | Driverless Cars Invested few shares | |
 | Impulse Invested over 200 shares | |
 | Artificial Intelligence Invested few shares | |
 | Hedge Favorites Invested over 20 shares | |
More Resources for Ensysce Stock Analysis
Reviewing Ensysce Biosciences commonly begins with financial statements and performance trends. Ratios and trend metrics help frame Ensysce Biosciences' operating context. Outlined below are key reports that provide context for Ensysce Biosciences Stock:Ensysce Biosciences has a market cap of 1.48 M, operating margin of -7.59%, ROE of -2.94%. Investing Opportunities can help frame allocation decisions. The allocation includes a position in Ensysce Biosciences within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To understand the process of investing in Ensysce Stock, visit our How to Invest in Ensysce Biosciences guide.Analysis related to Ensysce Biosciences should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Earnings Share -6.35 | Revenue Per Share | Quarterly Revenue Growth -0.86 | Return On Assets | Return On Equity |
Investors evaluate Ensysce Biosciences using market value and book value, each describing different facets of the business. Ensysce Biosciences' market capitalization is 1.48 M. A P/B ratio of 1.25 indicates the market values Ensysce Biosciences above its accounting book value. Enterprise value stands at 221.71 K. Value and price for Ensysce Biosciences are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
Value and price for Ensysce Biosciences are related but not identical, and they can diverge across cycles. For Ensysce Biosciences, key inputs include a P/B ratio of 1.25, a profit margin of -2.44%, ROE of -2.94%, and revenue of 5.21 M. Market price reflects the current exchange level formed by active bids and offers.